AMED · Insider Trading

Amedisys Inc

Every open-market purchase and sale reported by AMED officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Form 4 Filings
50
most recent
Open-Market Buys
0
code P
Sales
2
code S
Reporting Insiders
4
current holders
AMED — Recent Form 4 Transactions (latest 2025-08-14)
FiledInsiderRole TypeSharesValue
2025-08-14 Ivanetta Davis Samuels Director D −7,600 —
2025-08-14 Teresa L. Kline Director D −9,818 —
2025-08-14 Bruce D Perkins Director D −23,992 —
2025-08-14 Molly Joel Coye Director D −8,818 —
2025-08-14 Julie D Klapstein Director D −16,031 —
2025-08-14 Vickie L Capps Director D −9,818 —
2025-08-14 Paul B. K. Kusserow Director D −439,745 —
2025-08-14 Richard M Ashworth President and CEO MIXED −159,925 —
2025-08-14 Allyson Guidroz Chief Accounting Officer D −9,473 —
2025-08-14 Jeffrey A Rideout Director D −9,335 —
2025-08-14 Nick Muscato Chief Strategy Officer MIXED −35,899 —
2025-08-14 Denise M. Bohnert Chief Compliance Officer MIXED −20,141 —
2025-08-14 Scott G Ginn EVP, CFO & COO MIXED −94,443 —
2025-08-14 Jennifer G Griffin Chief Legal Officer D −20,173 —
2025-08-08 Allyson Guidroz Chief Accounting Officer A +2,015 —
2025-07-29 Nick Muscato Chief Strategy Officer F −31 −$3.04K
2025-07-29 Allyson Guidroz Chief Accounting Officer F −25 −$2.45K
2025-07-07 Bruce D Perkins Director G −105 —
2025-07-03 Allyson Guidroz Chief Accounting Officer F −461 −$44.43K
2025-06-30 Scott G Ginn EVP, CFO & COO F −2,327 −$228.12K
2025-06-03 Allyson Guidroz Chief Accounting Officer F −171 −$16.09K
2025-05-09 Allyson Guidroz Chief Accounting Officer Sell −374 −$35.90K
2025-05-06 Ivanetta Davis Samuels Director A +1,690 —
2025-05-06 Julie D Klapstein Director A +1,690 —
2025-05-06 Vickie L Capps Director A +1,690 —
2025-05-06 Allyson Guidroz Chief Accounting Officer F −273 −$26.21K
2025-05-06 Bruce D Perkins Director A +1,690 —
2025-05-06 Molly Joel Coye Director A +1,690 —
2025-05-06 Paul B. K. Kusserow Director A +1,690 —
2025-05-06 Jeffrey A Rideout Director A +1,690 —
2025-05-06 Teresa L. Kline Director A +1,690 —
2025-03-06 Allyson Guidroz Chief Accounting Officer Sell −2,041 −$187.83K
2025-02-24 Denise M. Bohnert Chief Compliance Officer F −1,083 −$98.65K
2025-02-24 Nick Muscato Chief Strategy Officer F −292 −$26.60K
2025-02-24 Scott G Ginn EVP, CFO & COO F −2,430 −$221.35K
2025-02-19 Richard M Ashworth President and CEO A +58,316 —
2025-02-19 Jennifer G Griffin Chief Legal Officer A +5,832 —
2025-02-19 Scott G Ginn EVP, CFO & COO MIXED +15,700 −$166.22K
2025-02-19 Denise M. Bohnert Chief Compliance Officer MIXED +5,167 −$61.58K
2025-02-19 Allyson Guidroz Chief Accounting Officer MIXED +1,906 −$23.52K
2025-02-19 Nick Muscato Chief Strategy Officer MIXED +5,181 −$60.28K
2024-12-31 Jennifer G Griffin Chief Legal Officer F −3,507 −$315.49K
2024-12-31 Richard M Ashworth President and CEO F −11,079 −$996.67K
2024-11-07 Nick Muscato Chief Strategy Officer A +10,421 —
2024-08-02 Allyson Guidroz Chief Accounting Officer A +2,179 —
2024-07-29 Allyson Guidroz Chief Accounting Officer F −102 −$9.97K
2024-07-29 Nick Muscato Chief Strategy Officer F −108 −$10.56K
2024-06-28 Scott G Ginn EVP, CFO & COO F −2,391 −$219.97K
2024-06-04 Allyson Guidroz Chief Accounting Officer F −175 −$15.95K
2024-05-07 Vickie L Capps Director A +1,678 —
AMED — Current Insider Holders
InsiderRole Shares HeldValue
Paul B. K. Kusserow Chief Executive Officer 353,670 $35.72M
Nick Muscato Chief Strategy Officer 32,620 $3.29M
Denise M. Bohnert Chief Compliance Officer 10,644 $1.07M
Allyson Guidroz Chief Accounting Officer 8,574 $865.89K
AMED Insider Trading FAQ
Who are the insiders at AMED?
4 officers, directors and 10%+ beneficial owners currently report holdings in AMED via SEC Form 4.
Are AMED insiders buying or selling?
Across the 50 most recent Form 4 filings for AMED, 0 were open-market purchases (code P) and 2 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is AMED insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent AMED filing is dated 2025-08-14.
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the AMED quote page; the site-wide leaderboard is on the insider transactions hub.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.